Most Read Articles
Elvira Manzano, Yesterday
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, Yesterday
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Low baseline HBsAg titre tied to seroclearance within 1 year after DAA treatment

25 Jun 2020
Hepatitis B is still widely prevalent worldwide despite effective vaccination programmes in many countries.

In patients with co-infection of hepatitis B (HBV) and hepatitis C (HCV) virus, low levels of hepatitis B surface antigen (HBsAg) prior to treatment with direct-acting antivirals (DAA) appear to lead to better HBV seroclearance, a recent study has found.

Researchers enrolled 79 patients (median age, 65 years; 53.2 percent male) co-infected with HBV and HCV who were undergoing DAA therapy. Serial measurements of HBsAg and HBV DNA were measured. The outcomes of interest were HBsAg dynamics and seroclearance, along with reactivation HBV, defined as >1-log increase in concentration.

The median HBsAg concentration was 73.3 IU/mL, while the corresponding HBV DNA level was 1.3 log10 IU/mL. Almost half (49.9 percent; n=39) had detectable HBV DNA levels.

Patients were followed up for a mean of 11 months after DAA treatment, during which 10.1 percent (n=8) saw HBsAg seroclearance. Four of these participants achieved this endpoint while still under DAA treatment; two reached seroclearance 3 months after DAAs, and the remaining two achieved this endpoint 6 months after treatment.

The resulting 12-month cumulative probability of HBsAg serolearance was 10.3 percent. Seroclearance was maintained throughout the remainder of the study period.

Pretreatment levels of HBsAg were significantly and inversely correlated with the likelihood of seroclearance (hazard ratio [HR], 0.328, 95 percent confidence interval, 0.137–0.787; p=0.012).

In more concrete terms, the cumulative incidence of HBsAg seroclearance at 12 months was 26.3 percent in those whose baseline levels fell below the cut-off value of 10 IU/mL. The corresponding incidence was 1.9 percent in those who fell above the threshold.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, Yesterday
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, Yesterday
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.